The research company Bioarctic has received an opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for exidavnemab for the treatment of multiple system atrophy (MSA). This is stated in a press release.

Exidavnemab is being developed as a new disease-modifying treatment for synucleinopathies such as MSA and Parkinson's disease.

"The fact that we have now received a positive recommendation for orphan drug designation for exidavnemab for MSA in the EU and equivalent approval in the US, and that we have been approved to include MSA patients in our ongoing Phase 2 study EXIST in Parkinson's disease is fully in line with our ambition to assist and develop drugs for a broader group of neurodegenerative diseases," says Gunilla Osswald, CEO of Bioarctic.